Skip to main content

Advertisement

SpringerLink
Log in

Treatment options for chronic cholestasis in infancy and childhood

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

Altered bile flow physiology leads to many complications commonly seen in patients with cholestatic liver disease, regardless of the etiology. For each individual patient, a coordinated and effective treatment strategy must address the presence and the severity spectrum of malabsorption, malnutrition, vitamin and micronutrient deficiencies, pruritus, xanthomata, ascites, and liver failure, which are attributed directly or indirectly to diminished bile flow. An aggressive approach to maximizing the nutritional status of the child is vital to ensure optimal growth and development. Protein-calorie and/or fat supplementation is best discussed early. Decreasing the percentage of dietary long-chain triglycerides, providing medium-chain triglycerides, and ensuring adequate essential fatty acid and adequate protein intake may be helpful. Fat-soluble vitamin (A, D, E, and K) levels and micronutrient levels must be carefully and serially monitored and supplemented as necessary. Because the mechanisms that mediate pruritus of cholestasis remain to be determined, the use of empirical therapies continues to be standard practice. Ursodeoxycholic acid may ameliorate pruritus. Antihistamines and rifampicin may also provide temporary relief for some children. Based on the evidence that increased central opioidergic tone is present in chronic cholestasis, the use of opiate antagonists is promising but has not been evaluated in children. Selected patients with refractory pruritus that have failed maximal medical therapy have benefited from partial external biliary diversion. Ongoing dialogue with the family regarding the indications for liver transplantation is reasonable. Optimization and adherence with the pretransplant medical management enhance the chances for a successful outcome from liver transplantation. Specific to the pediatric patient, optimizing growth, development and nutrition, minimizing discomfort and disability, and aiding the child and family in coping with the stress, social, and emotional effects of chronic liver disease remain paramount.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Bancroft J, Cohen MB: Intracranial hemorrhage due to vitamin K deficiency in breast-fed infants with cholestasis. J Pediatr Gastroenterol Nutr 1993, 16: 78–80.

    Article  PubMed  CAS  Google Scholar 

  2. Carlton VEH, Knisely AS, Freimer NB: Mapping of a locus for progressive familial intrahepatic cholestasis (Byler disease) to 18q21-q22, the benign recurrent intrahepatic cholestasis region. Hum Mol Genet 1995, 4: 1049–1053.

    Article  PubMed  CAS  Google Scholar 

  3. Bull LN, van Eijk MJT, Pawlikowska L, et al.: A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat Genet 1998, 18: 219–224.

    Article  PubMed  CAS  Google Scholar 

  4. Houwen RHJ, Baharloo S, Blankenship K, et al.: Genome screening by searching for shared segments: Mapping a gene for benigh recurrent intrahepatic cholestasis. Nat Genet 1994, 8: 380–386.

    Article  PubMed  CAS  Google Scholar 

  5. van Mil SW, van der Woerd WL, van der Brugge G, et al.: Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterol 2004, 127: 379–384.

    Article  CAS  Google Scholar 

  6. Strautnieks SS, Bull LN, Knisely AS, et al.: A gene encoding a liver specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet 1998, 20: 233–238.

    Article  PubMed  CAS  Google Scholar 

  7. Jansen PL, Strautnieks SS, Jacquemin E, et al.: Hepatocanalicular bile salt export protein deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterol 1999, 117: 1370–1379.

    Article  CAS  Google Scholar 

  8. De Vree JML, Jacquemin E, Dubuisson C, et al.: Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Hepatology 1996, 23: 904–908.

    Article  Google Scholar 

  9. Jacquemin E, Setchell KD, O’Connell NC, et al.: A new cause of progressive familial intrahepatic cholestasis: 3 beta-hydroxy-C27-steroid dehydrogenase/isomerase deficiency. J Pediatr 1994, 125: 379–384.

    Article  PubMed  CAS  Google Scholar 

  10. Bove KE, Heubi JE, Balistreri WF, et al.: Bile acid synthetic defects and liver disease: A comprehensive review. Pediatr and Devel Path 2004, 7: 315–334.

    Google Scholar 

  11. Stewart SM, Uauy R, Kennard BD, et al.: Mental development and growth in children with chronic liver disease of early and late onset. Pediatrics 1988, 82: 167–172.

    PubMed  CAS  Google Scholar 

  12. Stewart S, Uauy R, Waller DA, et al.: Mental and motor development, social competence and growth one year after successful pediatric liver transplantation. J Pediatr 1989, 114: 574–581.

    Article  PubMed  CAS  Google Scholar 

  13. O’Keefe SJ, El-Zayadi AR, Carraher TE, et al.: Malnutrition and immunocompetence in patients with liver disease. Lancet 1980, 2: 615–617.

    Article  PubMed  CAS  Google Scholar 

  14. Sokol RJ, Stall C: Anthropometric evaluation of children with chronic liver disease. Am J Clin Nutr 1990, 52: 203–208.

    PubMed  CAS  Google Scholar 

  15. Bucuvalas JC, Cutfield W, Horn H, et al.: Resistance to the growth-promoting and metabolic effects of growth hormone in children with chronic liver disease. J Pediatr 1990, 117: 397–402.

    Article  PubMed  CAS  Google Scholar 

  16. Holt RI, Baker AJ, Miell JP: The pathogenesis of growth failure in pediatric liver disease. J Hepatol 1997, 27: 413–423.

    Article  PubMed  CAS  Google Scholar 

  17. Protheroe SM: Feeding the child with chronic liver disease. Nutrition 1998, 14: 796–800.

    Article  PubMed  CAS  Google Scholar 

  18. Burke V, Danks DM: Medium chain triglyceride diet: its use in the treatment of liver disease. BMJ 1996, 2: 1050–1051.

    Article  Google Scholar 

  19. Chin SE, Shepherd RW, Thomas BJ, et al.: Nutritional support in children with end-stage liver disease: a randomized trial of branched-chain amino acid supplement. Am J Clin Nutr 1992, 56: 158–163.

    PubMed  CAS  Google Scholar 

  20. Bianchi G, Marzocchi R, Agostini F, et al.: Update on branched-chain amino acid supplementation in liver diseases. Curr Opin Gastroenterol 2005, 21: 197–200.

    Article  PubMed  CAS  Google Scholar 

  21. Socha P, Koletzko B, Swiatkowska E, et al.: Essential fatty acid metabolism in infants with cholestasis. Acta paediatr 1998, 87: 278–283.

    Article  PubMed  CAS  Google Scholar 

  22. Pettei MJ, Daftary S, Levine JJ: Essential fatty acid deficiency associated with the use of a medium-chain-triglyceride infant formula in pediatric hepatobiliary disease. Am J Clin Nutr 1991, 53: 1217–1221.

    PubMed  CAS  Google Scholar 

  23. Moreno LA, Gottrand F, Hoden S, et al.: Improvement of nutritional status in cholestatic children with supplemental nocturnal enteral nutrition. J Pediatr Gastroenterol Nutr 1991, 12: 213–216.

    Article  PubMed  CAS  Google Scholar 

  24. Wayman KI, Cox KL, Esquivel CO: Neurodevelopmental outcome of young children with extrahepatic biliary atresia 1 year after liver transplantation. J Pediatr 1997, 131: 894–898.

    Article  PubMed  CAS  Google Scholar 

  25. Roberts CC, Book LS, Chan GM, et al.: Rickets in children with cholestatic liver disease: evaluation and treatment. Pediatr Res 1981, 15: 544.

    Article  Google Scholar 

  26. Sokol RJ: Mechanism causing vitamin E deficiency during chronic childhood cholestasis. Gastroenterology 1983, 85: 1172–1182.

    PubMed  CAS  Google Scholar 

  27. Sokol RJ: Fat soluble vitamins and their importance in patients with cholestatic liver diseases. Gastroenterol Clin North Am 1994, 23: 673–705.

    PubMed  CAS  Google Scholar 

  28. Sokol RJ, Butler-Simon N, Conner C, et al.: Multicenter trial of d-alpha-tocopheryl polyethylene Glycol 1000 succinate for treatment of vitamin E deficiency in children with chronic cholestasis. Gastro 1993, 104: 1727–1735.

    CAS  Google Scholar 

  29. Bloomer JR, Boyer JL: Phenobarbital effects in cholestatic liver disease. Ann Intern Med 1975, 82: 310–317.

    PubMed  CAS  Google Scholar 

  30. Cynamon HA, Andres JM, Iafrate RP: Rifampin relieves pruritus in children with cholestatic liver disease. Gastroenterol 1990, 98: 1013–1016.

    CAS  Google Scholar 

  31. Yerushalmi B, Sokol RJ, Narkewicz MR, et al.: Use of rifampin for severe pruritus in children with chronic cholestasis. J Pediatr Gastroenterol Nutr 1999, 29: 442–447.

    Article  PubMed  CAS  Google Scholar 

  32. Balistreri WF: Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. J Pediatr Gastroenterol Nutr 1997, 24: 573–589.

    Article  PubMed  CAS  Google Scholar 

  33. Balistreri WF, A-Kader HH, Ryckman FC, et al.: Biochemical and clinical response to ursodeoxycholic acid administration in pediatric patients with chronic cholestasis. In Bile Acids as Therapeutic Agents. Edited by Paumgartner G, Stiehl A, Gerok W. Boston: Kluwer Academic; 1991: 323–333.

    Google Scholar 

  34. Narkewicz MR, Smith D, Gregory C, et al.: Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestatic liver disease. J Pediatr Gastroenterol Nutr 1998, 26: 49–55.

    Article  PubMed  CAS  Google Scholar 

  35. Kowdley KV: Ursodeoxycholic acid therapy in hepatobiliary disease. Am J Med 2000, 108: 481–486.

    Article  PubMed  CAS  Google Scholar 

  36. Wolfhagen FH, Sternieri E, Hop WC, et al.: Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997, 113: 1264–1269.

    Article  PubMed  CAS  Google Scholar 

  37. Bergasa NV: Treatment of the pruritus of cholestasis. Curr Treat Options Gastroenterol 2004, 7: 501–508.

    PubMed  Google Scholar 

  38. Ng VL, Ryckman FC, Porta G: Long-term outcome after partial external biliary diversion for intractable pruritus in patients with intrahepatic cholestasis. J Pediatr Gastro Nutr 2000, 30: 152–156.

    Article  CAS  Google Scholar 

  39. Emerick KM, Whitington PF: Partial external biliary diversion for intractable pruritus and xanthomas in Alagille syndrome. Hepatology 2002, 35: 1501–1506.

    Article  PubMed  Google Scholar 

  40. Kalicinski PJ, Ismail H, Jankowska I, et al.: Surgical treatment of progressive familial intrahepatic cholestasis: comparison of partial external biliary diversion and ileal bypass. Eur J Pediatr Surg 2003, 13: 307–311.

    Article  PubMed  CAS  Google Scholar 

  41. Kurbegov AC, Setchell KD, Haas JE, et al.: Biliary diversion for progressive familial intrahepatic cholestasis: Improved liver morphology and bile acid profile. Gastro 2003, 125: 1227–1234.

    Article  Google Scholar 

  42. Sokol RJ, Heubi JE, Iannaccone ST, et al.: Vitamin E deficiency with normal serum vitamin E concentrations in children with chronic cholestasis. N Engl J Med 1984, 310: 1209–1212.

    Article  PubMed  CAS  Google Scholar 

  43. Argao EA, Heubi JE, Hollis BW, et al.: D-alpha-tocopheryl-polyethylene glycol-1000 succinate enhances the absorption of vitamin D in chronic cholestatic liver disease of infancy and childhood. Pediatr Res 1992, 31: 146–150.

    Article  PubMed  CAS  Google Scholar 

  44. Sokol RJ, Guggenheim MA, Heubi JE, et al.: Frequency and clinical progression of the vitamin E deficiency neurologic disorder in children with prolonged neonatal cholestasis. Am J Dis Child 1985, 139: 1211–1215.

    PubMed  CAS  Google Scholar 

  45. Lane PA, Hathaway WE: Vitamin K in infancy. J Pediatr 1985, 106: 351–359.

    Article  PubMed  CAS  Google Scholar 

  46. Paumgartner G, Beuers U: Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002, 36: 525–531. With its increasing use for the treatment of various cholestatic disorders, this is an excellent concise review of the mechanisms underlying the postulated beneficial effects of ursodeoxycholic acid.

    Article  PubMed  CAS  Google Scholar 

  47. Hollands CM, Rivera-Pedrogo FJ, Gonzalez-Vallina R, et al.: Ileal exclusion for Byler’s disease: an alternative surgical approach with promising early results for pruritus. J Pediatr Surg 1998, 33: 220–224.

    Article  PubMed  CAS  Google Scholar 

  48. McDiarmid SV: Current status of liver transplantation in children. Pediatr Clin North Am 2003, 50: 1335–1774.

    Article  PubMed  CAS  Google Scholar 

  49. McDiarmid SV, Merion RM, Dykstra DM, et al.: Selection of pediatric candidates under the PELD system. Liver Transpl 2004, 10(10 Supplc 2):S23-S30.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Hepatology and Nutrition, Children’s Hospital Medical Center, 3333 Burnet Avenue, 45229-3039, Cincinnati, OH, USA

    William F. Balistreri MD

Authors
  1. Vicky Lee Ng MD, FRCPC
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William F. Balistreri MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ng, V.L., Balistreri, W.F. Treatment options for chronic cholestasis in infancy and childhood. Curr Treat Options Gastro 8, 419–430 (2005). https://doi.org/10.1007/s11938-005-0045-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-005-0045-5

Keywords

Search

Navigation